In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA to seek public comment on interim rule for wartime waivers of informed consent, Pendergast testifies.

Executive Summary

FDA RECEIVING "VERY FEW" REQUESTS FOR EMERGENCY RESEARCH INFORMED CONSENT WAIVERS, FDA Deputy Commissioner Mary Pendergast testified at a May 8 hearing of Rep. Shays' (R-Conn.) Government Reform/Human Resources Subcommittee. "FDA has tracked all INDs and [Investigational Device Exemptions] submitted under this ensure its adequacy for protecting research subjects and to ensure it is appropriately applied," Pendergast said. "To date, there have been very few submissions under this rule. We have received one IDE application and four IND applications under the emergency research rule."

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts